XJPX
4538
Market cap114mUSD
Oct 09, Last price
2,113.00JPY
1D
-0.09%
1Q
-1.99%
Jan 2017
-24.07%
Name
Fuso Pharmaceutical Industries Ltd
Chart & performance
P/E
8.97
P/S
0.29
EPS
235.56
Div yield, %
4.11%
Shrs. gr., 5y
-0.54%
Rev. gr., 5y
4.81%
Revenues
62.31b
+2.88%
Net income
2.01b
P
CFO
-6.22b
L+88.32%
Dividend
Mar 30, 202745 JPY/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Fuso Pharmaceutical Industries, Ltd. is a Japanese firm primarily involved in the development and commercialization of pharmaceutical goods. Their product range encompasses prescription medications, particularly injectables and solutions for artificial kidney dialysis, as well as various medical instruments and apparatus. Additionally, the company participates in real estate leasing. Established in 1937, Fuso Pharmaceutical's corporate headquarters are situated in Osaka, Japan.
Key people
Mikio Toda
President, Representative Director · since 1979
Mikihiro Toda
Senior Managing Director, Director of Business Planning, Representative Director · since 2025
Haruhiko Furuichi
Senior Executive Officer, Chief Director of General Affairs, Director of General Affairs, Director of Accounting · since 2025
Hideki Otani
Chief Director of Sales, Director · since 2021
Ryuji Higashi
Executive Officer, Director of Administration · since 2025
Masahiro Inoue
Executive Officer, Manger of Joto Factory · since 2025
Kazuhisa Iwamoto
Executive Officer, Director of Quality Assurance · since 2025
Mamoru Miyake
Executive Officer, Manager of Research and Development Center · since 2022
Taeko Okada
Executive Officer, Director of Production Administration in Main Production Unit · since 2024
Michikazu Saito
Executive Officer, Manager of Osaka Office in Main Sales Unit · since 2023
Junji Shiomi
Executive Officer · since 2022
Kiyoshi Tajima
Executive Officer, Manager of Tokyo 1st Office in Main Sales Office Unit, Manager of Tokyo Business Center · since 2023
Executive Officer, Chief Director of Reliability Guarantee · since 2023
Mitsuro Uotani
Executive Officer, Director of Distribution Promotion in Main Sales Unit · since 2022
Hirofumi Yamamoto
Executive Officer, Manager of Ibaraki Plant in Main Production Unit · since 2025
Kazuaki Yuasa
Executive Officer, Deputy Chief Director of Production · since 2025
Masanori Ito
Director · since 2021
Junichi Oka
Chief Director of Production, Director · since 2022
Yukari Ikeno
Independent Director · since 2025
Takashi Kashiwagi
Independent Director · since 2021
Valuation
Title JPY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026‑03 | 2025‑03 | 2024‑03 | 2023‑03 | 2022‑03 | 2021‑03 | 2020‑03 | 2019‑03 | 2018‑03 | 2017‑03 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||